Relizen for Hot Flashes: What the Pollen Trials Measured

Woman in her forties walking through flowering rye grass, the kind of pollen source behind relizen

Relizen is a Swedish flower pollen extract, not bee pollen, sold in the US by Bonafide. Its evidence is two small placebo controlled trials, 54 women in 2005 and 39 breast cancer survivors in 2024, plus studies with no placebo. A 2024 meta-analysis found that once only the controlled data were pooled, the benefit was no longer statistically significant.

Listen to this article, about 12 minutes. A synthetic voice reads the article and announces each section title as it begins; tables are read row by row and the questions at the end are left out.

Recorded 18 November 2026 from the article as published that day. Press a chapter to jump there; the highlighted line is what is playing. A play button sits beside every section heading, and once you scroll past this player a bar at the bottom of the screen keeps the controls in reach. Tap or click any sentence to hear the reading start from there.

On this page: every Relizen study read from PubMed with its size, comparison and length, the 2024 meta-analysis that pooled the controlled data, where the 65 percent figure comes from, and what five forum users reported.

Think you already know this? Five questions, one minute.

Every answer is on this page. Answer from what you know now; the page fills in the rest.

  1. 1. According to a 2020 review of bee remedies, what kind of pollen did the pollen extract studies use?

  2. 2. How many breast cancer survivors were randomised in the 2024 placebo trial?

  3. 3. What did the 2024 meta-analysis find when only the controlled studies were pooled?

  4. 4. In the 2005 trial, what share of women on placebo also reported fewer hot flushes?

  5. 5. What kind of study found the extract barely affected the CYP2D6 enzyme?

This page is an evidence review, not a shopping guide, and it recommends nothing. It reads the studies from PubMed, says how many women were in each and what they were compared with, and traces the percentages on the box. Checked on 18 November 2026.

What is actually in Relizen?

Pollen, minus the pollen grain. Bonafide’s Relizen page lists a 320 mg purified cytoplasmic blend per two tablet serving, made of two extracts: a pollen and pistil extract called PI 82 and a pollen extract called GC FEM, both under the Sérélys name. The Sérélys product brochure sells the same 320 mg blend as Pure CyTonin. In Europe it is Femal or Sérélys, which matters, because almost every study uses those names rather than Relizen.

The Memorial Sloan Kettering herb database gives the plants as rye grass, orchard grass and Scots pine, with maize for the pistil part, in a 75 to 25 split. These are wind pollinated plants. A 2020 review of bee remedies for menopause makes the point directly: the pollen studies tested extracts from wind pollinated plants, not pollen collected by bees. Anyone selling a jar of bee pollen on the strength of these trials has borrowed someone else’s homework.

It contains no hormone. A 2012 laboratory study found only low, subeffective traces of plant oestrogens and no uterine growth in rats, an animal finding, not a study of women.

Dried yellow flowers and a dish of fine plant powder, illustrating the pollen extract in relizen
The tablet is a 320 mg pollen and pistil blend; it contains no hormone.

How many women were in the Relizen placebo trials?

A total of 103 were randomised across two trials, with very different women in each. The first, a 2005 trial in Climacteric, randomised 64 menopausal women to two Femal tablets or two identical placebo tablets each morning for three months, after a one month run in. Fifty four finished it. The second, a 2024 trial in Gynecological Endocrinology, randomised 39 breast cancer survivors in Italy, 19 to the extract and 20 to placebo, for three months.

Everything else is observational, meaning no placebo group. An Italian study of 108 women in perimenopause and postmenopause, average age 53.8, scored symptoms before and after three months. A 2020 Naples study followed 57 women on the pollen tablets, 60 on soy isoflavones and 47 untreated for six months, all in natural menopause. Only the Italian study included perimenopausal women at all, and it had nobody to compare them with.

StudyWho and how manyCompared withLengthFunding as stated
Winther and colleagues, 200564 menopausal women, 54 finishedPlacebo tablets3 monthsNot in the abstract
De Franciscis and colleagues, 2020164 women in natural menopauseIsoflavones and no treatment, not randomised6 monthsNot in the abstract
Lello and colleagues, 2022108 women, peri and post menopauseNothing, before and after only3 monthsNot in the abstract
Bounous and colleagues, 202439 breast cancer survivorsPlacebo3 monthsNot in the abstract
Acquarulo and colleagues, 20245 studies, 420 women pooledMeta-analysisNot applicableNone reported

What did the trials find on hot flashes?

The 2005 trial is the result the brand leans on. In the abstract, 65 percent of women on the extract reported fewer hot flushes against 38 percent on placebo, and diary counts fell 27 percent more than on placebo after three months. The groups started level, but this is one trial of 54 finishers, run over 20 years ago.

The 2024 trial is weaker than its headline. Its abstract reports that hot flash numbers fell in the extract group by month three compared with that group’s own starting point. It does not report the comparison that would settle it, the extract group against the placebo group on hot flash count. With 19 women in one arm, that is not a small omission.

Then the pooled view. A 2024 meta-analysis in Menopause found five usable studies, one randomised and four observational, with 420 women. Across everything, scores improved after three months. But when the controlled studies were pooled, the results were no longer statistically significant, and the authors suggest the gains in uncontrolled studies may have been placebo effect. They also found no significant harms. That review was published before the 2024 breast cancer trial, so it could not include it.

Bar chart of relizen trial responders, pollen extract 65 percent against placebo 38 percent
From the abstract of the 2005 Climacteric trial of Femal, the same extract sold as Relizen. One trial of 54 women who finished; the 2024 trial abstract gives no comparable arm figures.

Who is behind the Relizen research?

Mostly people close to the product, as far as the public record shows. One of the three authors of the 2005 trial is listed as C Hedman, and a Christer Hedman is named as an inventor on a Natumin Pharma AB patent for a pollen and pistil extract combination. This page could not read the trial’s funding statement or confirm they are the same person, so treat it as a question, not a finding.

A 2020 review by 15 menopause specialists calls the extract safe and non oestrogenic and names it throughout by its trade name, PureCyTonin. That reads more like product literature than independent appraisal. The only review with no conflicts reported is the meta-analysis that found no significant effect once placebo was counted.

Where do the 65 percent and 7 in 10 figures come from?

From the same small trial, mostly. Bonafide’s page for clinicians describes a randomised, double blind trial in 54 women where 65 percent saw fewer daily hot flashes after three months. That matches the 2005 abstract, minus the 38 percent placebo figure that gives it meaning. The consumer page says hot flash frequency fell for 7 in 10 women after 12 weeks and cites three placebo controlled trials. PubMed found two in menopausal women, and the 7 in 10 figure could not be traced to a paper. A rival brand’s sales sheet quotes this extract at 22 percent fewer hot flashes beside its own uncontrolled figure, as our review of the Estrovera rhubarb extract trials explains.

Claim you may seeWhere it comes fromWhat the source shows
65 percent had fewer hot flashesBonafide clinician pageMatches 2005 trial; 38 percent on placebo also improved
7 in 10 women after 12 weeksBonafide consumer pageNo paper found with that figure
Three placebo controlled trialsBonafide consumer pageTwo found on PubMed in menopausal women
Hormone free2012 laboratory studyTrace plant oestrogens; no effect in rats

What is known about Relizen and breast cancer treatment?

This is where the pollen extract has its real following, and where the evidence is thinnest. Tamoxifen relies on the liver enzyme CYP2D6, which some antidepressants used for hot flashes block. The 2015 study found the extract barely touched that enzyme in liver cells in a dish, inhibition between minus 6.53 and 10.67 percent, against 84.05 percent for the reference drug. That is a test tube result, not a study of women taking tamoxifen.

The sources disagree with each other here. The Memorial Sloan Kettering page, last updated 23 May 2025, says no studies have been conducted in cancer populations. The 2024 trial of 39 breast cancer survivors had been published a year earlier. Both can be read today, and the reader deserves to know they conflict.

Anyone who has had breast cancer, or takes tamoxifen or an aromatase inhibitor, has a specific reason to talk to their oncology team before adding any supplement. Bleeding after 12 months without a period, or bleeding that is new, heavy or unusual, needs a doctor whatever else is going on. Our page on bleeding after menopause sets out what the guidance says.

What do NICE and the Menopause Society say about supplements like this?

Neither names Relizen. The Menopause Society’s 2023 nonhormone therapy position statement lists supplements and herbal remedies as not recommended for hot flashes; whether it names pollen extract specifically could not be confirmed for this page. NICE NG23, last updated 15 April 2026, says in recommendation 1.4.6 that the safety, quality and purity of constituents in unregulated preparations may be unknown, and in 1.4.7 that there is some evidence for isoflavones or black cohosh. Pollen extract is not mentioned.

The FDA explains that dietary supplements need no approval for safety or effectiveness before sale, which is a lot of faith to place in some grass.

What do people taking Relizen report?

Most of the accounts come from breast cancer forums, not menopause ones. Reddit search for the past year turned up ten comments and one thread from six users who mention Relizen, five of them describing their own use. One user on tamoxifen, posting the same account several times between July and October 2026, said their oncologist suggested it and hot flashes dropped from more than 12 a day to about two. A user with metastatic breast cancer in September 2026 said neither Relizen nor gabapentin helped. Another, on ovarian suppression and an aromatase inhibitor, said in November 2026 that it was not doing enough.

Woman in her early forties reading at a laptop in the evening, looking up relizen accounts
Most accounts of taking it come from breast cancer forums, not menopause ones.

A user in r/Menopause who cannot take hormone therapy after breast cancer wrote in July 2026 that they had taken it for years and found it helpful. Another in October 2026 credited it, together with switching to percale bedding, which makes it impossible to say which did the work. The tamoxifen user called it bee pollen, which it is not.

These are things people report, not findings. Hot flashes change on their own over months and years, and a forum cannot separate the tablet from placebo. The pattern worth noting is who is asking: people for whom hormone therapy is off the table.

What is worth asking before buying any menopause supplement?

The same questions work for every bottle on the shelf. Our reviews of the Amberen perimenopause trials and the Estroven Complete trials ask them of other brands, and our page on natural relief for hot flashes covers the approaches with stronger evidence.

  • Did the trial enrol women at my stage, perimenopause or postmenopause?
  • What happened in the placebo group, in numbers?
  • How many women finished, and how long did it last?
  • Who paid for the trial, and has anyone independent repeated it?
  • Do I take tamoxifen, an aromatase inhibitor or any other prescription a pharmacist should know about?
  • Do I have a pollen or plant allergy worth mentioning?

Questions to ask a pharmacist before buying any menopause supplement

Drawn from how this product’s studies read. Tick each one you have an answer to. It scores nothing and names no product as advised.

General information only. Anyone treated for breast cancer should speak to their oncology team before adding a supplement. Bleeding after 12 months without a period needs a doctor.

Frequently asked questions

Is Relizen the same as Femal or Sérélys?

The same extract under different names. A 2015 paper lists Relizen, Sérélys, Femal and Femalen as trade names for purified Swedish pollen extract.

Is Relizen bee pollen?

No. A 2020 review notes the pollen studies used extracts from wind pollinated plants, not pollen collected by bees.

How long were the Relizen trials?

Three months of treatment in both placebo trials. The Naples study ran six months but had no placebo group.

Was Relizen tested in perimenopause?

Only in one observational Italian study of 108 women in peri and postmenopause, with no comparison group.

Has the FDA approved Relizen?

No. Supplements are sold without FDA approval for safety or effectiveness, as the FDA’s own guidance explains.

Were side effects reported in the trials?

The 2024 meta-analysis found no significant adverse effects, though the trials were small and short.

Finished the page? The same five questions from the top, to see what stuck.


This article is general information, not medical advice, and is not a substitute for care from a qualified healthcare professional. Speak to your doctor about your own situation.

Questions and corrections

Platform rules change without notice. If you hit something different when you applied, say so here and we will verify it and update the page.

Leave a Reply

Your email address will not be published. Required fields are marked *